Lesbre J P, Lalau J D, Jaubourg M L, Maarek-Charbit M
Service de Cardiologie B, Hôpital Sud, Amiens.
Ann Cardiol Angeiol (Paris). 1988 Apr;37(4):205-10.
A randomised, crossover, double-blind study was carried out in sixteen coronary patients with stable effort angina to compare the effects of verapamil (360 mg) and propranolol (120 mg). All the patients received placebo for 2 days, underwent a coronary angiography which confirmed coronary heart disease and were then randomised into two groups to receive an initial treatment of either verapamil or propranolol for three days. The patients then took placebo for 3 days, then the second drug after cross-over also over 3 days. The therapeutic efficacy was assessed by stress testing on a treadmill (Bruce protocol) with automated analysis of the results (Case-Marquette), carried out on the last day of each of the phases with placebo and the test drug. The duration of the stress test increased significantly with propranolol (p less than 0.01) and verapamil (p less than 0.05) with respect to placebo. In comparison with placebo, propranolol and verapamil resulted in a similar decrease in ST segment depression at the time of maximum effort (p less than 0.01). The resting systolic blood pressure decreased with propranolol (p less than 0.02) and verapamil (p less than 0.01), whereas resting diastolic blood pressure only decreased with verapamil (p less than 0.01). Resting heart rate decreased during the propranolol phase (p less than 0.001). The systolic blood pressure at the time of maximum effort decreased especially with propranolol (p less than 0.05), whereas the diastolic blood pressure on exertion decreased during the verapamil phase (p less than 0.01). Heart rate during exertion only showed a significant decrease with propranolol (p less than 0.001) as compared with placebo.(ABSTRACT TRUNCATED AT 250 WORDS)
对16例稳定型劳力性心绞痛冠心病患者进行了一项随机、交叉、双盲研究，以比较维拉帕米（360毫克）和普萘洛尔（120毫克）的效果。所有患者接受2天安慰剂治疗，进行冠状动脉造影以确诊冠心病，然后随机分为两组，接受为期3天的维拉帕米或普萘洛尔初始治疗。患者随后服用3天安慰剂，然后交叉服用另一种药物，同样为期3天。在每个使用安慰剂和试验药物阶段的最后一天，通过跑步机压力测试（布鲁斯方案）并自动分析结果（Case-Marquette）来评估治疗效果。与安慰剂相比，普萘洛尔（p<0.01）和维拉帕米（p<0.05）使压力测试持续时间显著增加。与安慰剂相比，普萘洛尔和维拉帕米在最大运动量时导致ST段压低有相似程度的降低（p<0.01）。静息收缩压在服用普萘洛尔（p<0.02）和维拉帕米（p<0.01）时下降，而静息舒张压仅在服用维拉帕米时下降（p<0.01）。在普萘洛尔治疗阶段静息心率下降（p<0.001）。最大运动量时的收缩压尤其在服用普萘洛尔时下降（p<0.05），而运动时的舒张压在维拉帕米治疗阶段下降（p<0.01）。与安慰剂相比，运动时的心率仅在服用普萘洛尔时显著下降（p<0.001）。（摘要截选至250字）
